Matthew Ellis, MD PHD
NPI 1669495685 · West · Owned by Dr. Tanya Reed
Discover current approach to tx selection patterns between T-DXd + P and existing regimens for 1L HER2+ a/mBC
Driving dimension: Tx selection patterns between T-DXd + P and existing regimens for 1L HER2+ a/mBC
Impact context
Limited professional network footprint. Opportunistic engagement only; use any interaction to assess genuine scientific interest.
Knowledge context
Limited evidence exposure in this area. Lead with core clinical data and foundational context, keeping it clear and grounded in patient relevance. Let their questions set the pace for going deeper.
Suggested materials
- DESTINY-Breast09 (D967UC00001) Fam-Trastuzumab Deruxtecan-nxki (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-Positive First Line Metastatic Breast Cancer (Reactive Slide Deck; MED-US-TRAS-00436): Slides 16–37
- DESTINY-Breast09 Medical Q&A (FAQ Document; MED-US-TRAS-00437): All questions from DESTINY-Breast09 Efficacy Results, DESTINY-Breast09 Key Subgroup Analysis Results
- Discussion Guide: T-DXd+ P in 1L HER2-Positive mBC (Reactive Slide Deck; MED-US-TRAS-00412): Slides 9–14, 26–36, 42–47
Feedback timeline
Discover current approach to QoL vs other regimens
Driving dimension: QoL vs other regimens
Impact context
Limited professional network footprint. Opportunistic engagement only; use any interaction to assess genuine scientific interest.
Knowledge context
Limited evidence exposure in this area. Lead with core clinical data and foundational context, keeping it clear and grounded in patient relevance. Let their questions set the pace for going deeper.
Suggested materials
Feedback timeline
Discover current approach to belief in treatment to progression in 1L
Driving dimension: Belief in treatment to progression in 1L
Impact context
Limited professional network footprint. Opportunistic engagement only; use any interaction to assess genuine scientific interest.
Knowledge context
Limited evidence exposure in this area. Lead with core clinical data and foundational context, keeping it clear and grounded in patient relevance. Let their questions set the pace for going deeper.
Suggested materials
- DESTINY-Breast09 (D967UC00001) Fam-Trastuzumab Deruxtecan-nxki (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-Positive First Line Metastatic Breast Cancer (Reactive Slide Deck; MED-US-TRAS-00436): Slides 8, 16–37
- Discussion Guide: T-DXd+ P in 1L HER2-Positive mBC (Reactive Slide Deck; MED-US-TRAS-00412): Slides 4–8
- DESTINY-Breast09 Medical Q&A (FAQ Document; MED-US-TRAS-00437): All questions from DESTINY-Breast09 Efficacy Results